Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Deborah Glasser: Nasdaq Bell Celebrating FDA Approval of Novel ITP Therapy
Deborah Glasser/LinkedIn
Sep 20, 2025, 13:35

Deborah Glasser: Nasdaq Bell Celebrating FDA Approval of Novel ITP Therapy

Deborah Glasser, Head of Specialty Care for Sanofi, shared a post on LinkedIn:

”Yesterday, I had the opportunity to ring the Nasdaq closing bell, surrounded by Sanofi colleagues and representatives from the Platelet Disorder Support Association – PDSA. I’m so grateful that PDSA joined us on this special occasion to celebrate ITP Awareness Month, and to recognize the recent FDA approval of a novel treatment. By targeting root causes through multi-immune modulation, this new medicine represents a significant step forward for patients living with immune thrombocytopenia (ITP), a complex immune dysregulation disease, which can cause symptoms that disrupt daily life.

This moment reflects the power of science, collaboration, and our shared commitment to improving patient outcomes. At Sanofi, we continue to push the boundaries of immunoscience to make a meaningful difference for individuals affected by rare conditions like ITP.”

ITP

Stay updated with Hemostasis Today.

Bleeding Disorder Deborah Glasser FDA Hematology Hemostasis Today Immune thrombocytopenia ITP ITP Therapy PDSA Platelet Disorder Platelet Disorder Support Association Sanofi
NewsFeed